The guidance is intended to assist potential applicants in determining when an application for a synthetic peptide drug product (synthetic peptide) that refers to a previously approved peptide drug product of recombinant deoxyribonucleic acid (rDNA) origin (peptide of rDNA origin) should be submitted as an ANDA under section 505(j) of the FD&C Act rather than as a new drug application (NDA) under section 505(b) of the FD&C Act.
![](https://static.wixstatic.com/media/nsplsh_c347636f27134e099a02845f507f71dc~mv2.jpg/v1/fill/w_147,h_98,al_c,q_80,usm_0.66_1.00_0.01,blur_2,enc_auto/nsplsh_c347636f27134e099a02845f507f71dc~mv2.jpg)
Specifically, this guidance provides recommendations for evaluating whether an ANDA submission is appropriate for a synthetic peptide that references any of the following five previously approved peptide drug products of rDNA origin: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide.